Arshad Malik, MD
Cardiovascular Disease · Merrillville, INNPI 1386630325
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,569 of the $3,147 with a category attached, or 81.6%. It is spread thinly across 37 manufacturers, the largest accounting for just 12.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,346 and has fallen 81.7% since, to $246 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in IN, where the typical reported total is $2,452.
Across 105 payments — averaging $29.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cook Incorporated$405
- Cook Medical LLC$397
- Novartis$376
- Johnson & Johnson$182
- EKOS Corporation$168
- Cardiovascular Systems Inc.$168
- plus $1K from 31 others
Across 100 payments — averaging $3267.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$140K
- Boehringer Ingelheim International GmbH$67K
- Cleerly, Inc.$31K
- Lexicon Pharmaceuticals, Inc.$28K
- Boehringer Ingelheim Pharma GmbH & Co.kg$22K
- Currax Pharmaceuticals LLC$17K
- plus $21K from 2 others
What the payments were for
- Travel & lodging$57818%
- Food & beverage$2,56982%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cook Incorporated | 2 | $405 |
| Cook Medical LLC | 12 | $397 |
| Novartis | 22 | $376 |
| Johnson & Johnson | 4 | $182 |
| EKOS Corporation | 2 | $168 |
| Cardiovascular Systems Inc. | 5 | $168 |
| Amgen | 9 | $150 |
| Inspire Medical Systems, Inc. | 2 | $149 |
| Abbott | 2 | $116 |
| Boston Scientific | 2 | $100 |
| Astellas Pharma US Inc | 1 | $78 |
| Merck | 5 | $73 |
| Endologix LLC | 1 | $66 |
| Scpharmaceuticals Inc. | 2 | $54 |
| Itamar Medical Inc | 1 | $52 |
| Cordis US CORP. | 3 | $52 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $51 |
| Abiomed | 1 | $47 |
| Regeneron Healthcare Solutions, Inc. | 2 | $46 |
| Novo Nordisk | 2 | $43 |
| AstraZeneca | 3 | $40 |
| GSK | 2 | $35 |
| Philips North America LLC | 1 | $32 |
| Bard Peripheral Vascular, Inc. | 2 | $31 |
| Lantheus Medical Imaging, Inc. | 1 | $28 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Eisai Inc. | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| Teleflex LLC | 1 | $19 |
| Edwards Lifesciences | 1 | $17 |
| Lilly USA, LLC | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
| AbbVie | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,147 in reported general payments places this provider in the 50th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 78 | $106,498 |
| EliquisApixaban | 66 | $80,858 |
| OzempicSemaglutide | 56 | $78,551 |
| JardianceEmpagliflozin | 44 | $48,886 |
| XareltoRivaroxaban | 22 | $27,334 |
| JanuviaSitagliptin Phosphate | 14 | $22,265 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $20,745 |
| VerquvoVericiguat | 11 | $14,377 |
| TradjentaLinagliptin | 17 | $13,871 |
| BrilintaTicagrelor | 13 | $9,820 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $4,008 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $3,387 |
| Metoprolol Succinate | 209 | $2,813 |
| ClopidogrelClopidogrel Bisulfate | 201 | $2,337 |
| Pantoprazole Sodium | 177 | $2,057 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $376 | $106,49878 claims |
| Novo NordiskOzempic | $43 | $78,55156 claims |
| Boehringer IngelheimJardiance, Tradjenta | $14 | $62,75761 claims |
| MerckJanuvia, Verquvo | $73 | $36,64225 claims |
| Johnson & JohnsonXarelto | $182 | $27,33422 claims |
| GSKTrelegy Ellipta | $35 | $20,74525 claims |
| AstraZenecaBrilinta | $40 | $9,82013 claims |
| AbbVieSynthroid | $14 | $1,31920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 408 cardiovascular disease providers in Indiana.
Other cardiovascular disease in Merrillville
- Mihas KodencheryMerrillville$20K
- Majd KanbourMerrillville$18K
- Andre ArtisMerrillville$17K
- John MillerIndianapolis$354K
- David KovacichIndianapolis$327K
- Wai LeeElkhart$321K
- Anas SafadiHobart$295K
- Lawrence RinkBloomington$280K
- Vijay RaoIndianapolis$247K
- Steven SteinhublLafayette$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.